Mitoxantrone in secondary progressive multiple sclerosis: a review of toxicity in 41 patients

Scott Peak, Denice D Tsao-Wei and Marc C Chamberlain

Aims: The primary objective of this study was to summarize the toxicity of mitoxantrone treatment of secondary progressive multiple sclerosis (SPMS), with particular focus on cardiotoxicity, hematological and nonhematological toxicities.

Methods: A total of 41 patients with SPMS were treated with mitoxantrone and their charts retrospectively reviewed for efficacy of treatment and frequency of toxicity.

Results: Mitoxantrone toxicity was common but treatable, and was effective in achieving disease stabilization in the majority of patients.

Conclusions: When monitored appropriately, mitoxantrone is safe and effective in the treatment of SPMS.